Micronoma discoveres novel OncobiotaLUNG, A novel liquid biopsy test for the detection of lung carcinoma.
The OncobiotaLUNG test is the first blood microbiome-guided liquid biopsy with proven effectiveness for detecting cancer in early stages.
Detection of lung cancer at initial stages leads to higher survival rate. Every year in U.S., lung cancer accounts for nearly 25% of all cancer-related deaths, with more people die from lung cancer than from colon, breast, and prostate cancers combined.
Patients undergoing an imaging test (eg, low-dose CT scan (LDCT) resulted in indeterminate pulmonary nodule, then additional imaging are performed (eg, more LDCTs, PET-CT scans). Then, if the suspicion remains the same, they are sent for a lung biopsy. However, with 95% of imaged lung nodules turning out to be benign, the current patient journey can be slow and risky, involving potentially invasive but unnecessary tissue biopsies. In contrast, with a simple blood sample, OncobiotaLUNG diagnostic test helps clinicians determine the high and low risk of detected lung nodular malignancy, and the diagnostic result meets or exceeds the current standard of care.
Food and Drug Administration (FDA) grants breakthrough device designation for OncobiotaLUNG or lung carcinoma detection.
